Febuxostat (Teijin/Ipsen/TAP)
- PMID: 16312139
Febuxostat (Teijin/Ipsen/TAP)
Abstract
Febuxostat (TEI-6720; TMX-67), an oral non-purine, selective inhibitor of xanthine oxidase (NP-SIXO), is being developed by Teijin, with licensees Ipsen and TAP Holdings, for the potential treatment of gout. In February 2005, it was reported that launch in Japan was expected to be delayed for several years due to the need for additional clinical trials; in May 2005, an EU filing was expected by the end of 2005.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous